SMMT Research Report Countdown: Bearish on Ivonescimab's Clinical Prospects

Overview

Bernstein initiates coverage of Summit Therapeutics with an 'Underperform' rating and a $7.70 target price, implying a 56% downside. The report focuses on the HARMONi6 ASCO presentation (May 31, 2026), FDA BLA approval prospects, and ivonescimab's clinical trial expectations in first-line NSCLC, colorectal cancer, and other indications. The core conclusion is that the PD-1/VEGF bispecific antibody ivonescimab fails to demonstrate clinically meaningful advantages over existing anti-PD-1 plus anti-VEGF two-drug combinations; historically, such drug combinations have repeatedly failed to translate PFS benefits into OS benefits in Phase 3 trials. As a clinical-stage company entirely dependent on ivonescimab as its sole pipeline, SMMT faces concentrated risks of multiple trial failures.

Core views

**HARMONi6 ASCO Presentation Expectations and Fundamental Analysis** The report expects HARMONi6 at ASCO 2026 plenary session (May 31) to present interim PFS data for first-line non-small cell lung cancer (NSCLC, all patients). Based on trial design, event triggers, and historical trial timelines, Bernstein's base case is that the interim OS analysis fails to meet significance (HR >0.722). Despite an encouraging PFS HR of 0.60, historical patterns from PD-1 + anti-VEGF combination trials (LEAP-006/007, IMpower150, etc.) show PFS benefits often significantly attenuate in OS analyses, with an average attenuation of 0.31 (range 0.17-0.47). Applying this pattern, HARMONi6's final OS HR may range between 0.82-0.91, below the clinically meaningful threshold (<0.8) for NSCLC. **Limited Market Size and Intensifying Competition in Second-line EGFRm NSCLC** The HARMONi BLA application has been accepted by the FDA, with a PDUFA date of November 14, 2026. However, the indication faces multiple headwinds: (1) Small market—only 31.5% of first-line patients proceed to second-line treatment, with ~7,700 new annual cases and a US TAM of ~$900M; (2) Precedent failure—Merck voluntarily withdrew HER3-DXd's BLA in May 2025 due to HERTHENA-Lung02 Phase 2 trial's OS failing significance, reflecting FDA's heightened OS requirements; (3) Intensifying competition—Trop-2 ADCs (e.g., Dato-DXd + osimertinib) show superior data in similar patients (mPFS 12 months, mOS 21.5 months, HR 0.60), posing a direct threat to ivonescimab; (4) Regulatory uncertainty—While HARMONi showed significant PFS improvement (HR 0.52), OS missed the primary endpoint (HR 0.79, p=0.057), with OS HR upper bounds >1 (1.30-1.32) in North American and EU patient subgroups, suggesting regional safety concerns. Bernstein rates FDA approval as 'coin toss,' with limited commercial prospects even if approved, given Rybrevant (amivantamab) already capturing the market with similar efficacy. **Low Success Probability for Two Key First-line NSCLC Trials** HARMONi-3 (patients with any PD-L1 expression, chemotherapy + ivonescimab vs. chemotherapy + pembrolizumab) and HARMONi-7 (PD-L1 ≥50% patients, ivonescimab monotherapy vs. pembrolizumab monotherapy) set higher success barriers than the second-line trial: both trials have OS as the primary endpoint, requiring significant improvement. Bernstein calculates probability of technical success (PTS) at 16% (HARMONi-7) and 21% (HARMONi-3). Downside factors include: (1) PD-1/VEGF bispecific antibodies cannot outperform two-drug combinations—preclinical studies (including ivonescimab, HB0025, CLV006, HLX37, BNT-327, etc.) fail to demonstrate synergistic advantages over separate dosing, with some models showing no improvement over controls; (2) Historical failure patterns repeating—LEAP-007, LEAP-006, IMpower150, etc., show adding anti-VEGF to PD-1/L1 fails to improve OS despite PFS benefits; (3) Worse global patient response—HARMONi-2 (China, PD-L1 ≥1%) preliminary OS HR 0.777 failed significance, while HARMONi-7's PD-L1 high-expression patients respond better to pembrolizumab, requiring ivonescimab to clear a higher efficacy benchmark. Compared to historical trials like KEYNOTE-024, KEYNOTE-189, successful HARMONi-3 nsq cohort would need mOS ~25 months, HARMONi-7 ~35-36 months, targets difficult to achieve given ivonescimab's PFS-OS attenuation pattern. **Extremely Dim Prospects for Colorectal Cancer MSS First-line Trial** HARMONi-GI3 evaluates ivonescimab + chemotherapy vs. bevacizumab + chemotherapy in mFOLFOX6 backbone for MSS/pMMR patients. Bernstein assigns only a 5% PTS to this trial. Key reasons include: (1) MSS tumors are 'cold,' showing poor response to immunotherapy—CheckMate9XB, LEAP-017, AtezoTRIBE, etc., show adding anti-PD-1/L1 to bev + chemotherapy offers no OS benefit, with some showing OS deterioration; (2) Insufficient preliminary data—The only preclinical data comes from a small single-arm study at ESMO 2024 (22 patients), ORR 82% vs. historical bev + FOLFOXIRI's 65%, but small sample, potential selection bias, and unclear true 9-month PFS improvement; (3) Trial design risks—Global trial patients may respond worse to bevacizumab + chemotherapy (compared to Chinese single-arm data), making success thresholds effectively meaningless.

Analysis framework

The report employs an 'outside-in' event forecasting approach, combining clinical trial design analysis, historical benchmarking, and company fundamental assessment. For HARMONi6 expectations, Bernstein starts with the publicly available trial protocol (statistical analysis plan, information fraction, critical value thresholds, etc.), uses trial design experience to estimate interim OS analysis event triggers, and infers the base case of non-significance based on the absence of press releases. For efficacy degradation pattern analysis, the report reviews recent PD-1/VEGF combination trial data (LEAP-006/007, IMpower150, ATLAS, ORIENT-31, etc.), finding a consistent PFS HR to OS HR attenuation of 0.31, and applies this to extrapolate ivonescimab's final OS HR ranges across trials. Market size assessment uses real-world clinical data (US Flatiron cohort) to estimate second-line patient pools, considering treatment duration and pricing to derive TAM. Preclinical data review compares multiple PD-L1/VEGF bispecific antibodies' published preclinical studies, noting the general lack of direct comparison with PD-1/L1 + VEGF two-drug combinations, thus failing to demonstrate bispecific antibodies' synergistic advantages. PTS calculations use a standard biopharma framework: 36% baseline (oncology OS primary endpoint trials), +10% credit (acknowledging HARMONi-2/-6 Chinese data PFS benefits), -25% major deduction (no bispecific superiority evidence, historical attenuation patterns, no safety differentiation), arriving at HARMONi-3 21%, HARMONi-7 16%, HARMONi-GI3 5% PTS.

Methodology notes

• Event Gaming & Behavioral FinanceExpectation Gap/Expectation Management

  The market's expectations for PD-1/VEGF bispecific antibody ivonescimab diverge from clinical data reality. Investors overly believe 'this time is different,' but historically such combinations have repeatedly failed in trials.

  Expectation gap analysis helps identify market pricing deviations from true clinical prospects. Benchmarking historical similar trial failures (LEAP, IMpower150, etc.) reveals investors overestimate ivonescimab's ability to break through existing challenges. The report corrects this optimism with hard data (PFS-OS attenuation patterns, preclinical negative data).

• Industry/Sector Analysis FrameworkSupply-demand framework

  Second-line EGFRm NSCLC market patient pool is limited (only 31.5% of first-line patients proceed to second-line), and new competitors (Trop-2 ADCs, re-dose osimertinib, etc.) are rapidly expanding, squeezing ivonescimab's market space.

  The supply-demand framework highlights dual pressures of limited market size and intensifying competition. Even if ivonescimab is approved, its market share faces erosion from Rybrevant (already approved, similar efficacy) and emerging therapies. The report quantifies TAM (~$900M) and penetration assumptions (25%) to show commercial limitations.

• Competition & Strategy FrameworkMoat / competitive advantage

  Ivonescimab's purported scientific advantage as a bispecific antibody (one molecule targeting both PD-1 and VEGF) lacks preclinical and clinical data support, showing no difference or disadvantage compared to two-drug combinations, hence no competitive barrier.

  Moat assessment focuses on sustainable competitive advantages. The report notes ivonescimab lacks mechanism-level evidence supporting superiority over existing combination therapies; multiple preclinical models fail to show bispecific antibodies' synergistic effects; clinically, PFS-OS attenuation patterns mirror two-drug combinations. This makes ivonescimab easily replaceable.

• Cycle & Sentiment FrameworkInflection Point Analysis

  PD-1/VEGF combination therapy's clinical prospects have reached an inflection point in 2024-2025, shifting from early hope to 'attenuation phase'—not only ivonescimab but also BioNTech faces similar challenges, signaling overall failure of this strategy.

  Inflection point framework identifies industry trend shifts. The report notes Merck's HER3-DXd BLA withdrawal in 2025 signals FDA's stricter OS requirements. PD-1/VEGF is no longer a hotspot, with Trop-2 ADCs and other models gaining dominance. Ivonescimab faces a declining product direction and stricter regulatory environment.

• Company Fundamentals & Financial FrameworkFree cash flow analysis

  SMMT's $599M cash reserve (1Q26) is primarily spent on multiple Phase 3 trials. If multiple trials fail (base case), the company faces funding pressure, potentially leading to shareholder dilution or pipeline abandonment.

  Free cash flow analysis reveals the company's 'runway.' As a clinical-stage pure R&D company with no revenue buffer, SMMT's cash is outflow only. If all three HARMONi trials fail (accumulated probability 2%-5%), rapid financing or acquisition/shutdown is needed. This cash pressure will emerge immediately after trial results.

• Valuation methodsDCF Discounted Cash Flow

  Bernstein uses DCF, assuming multiple trial failures and only HARMONi (second-line EGFRm NSCLC) success as a pessimistic scenario, discounted at 12% WACC to 2040, arriving at a $7.70 target price.

  DCF method weights low-probability success scenarios' NPV projections into share price, reflecting downside risk. The report's DCF inputs include: HARMONi second-line only 25% penetration, first-line trial failures, Phase 3 GI3 failure, etc., and revenue paths plateauing post-2035. Compared to consensus overestimating trial success probability and market penetration, Bernstein's target price reflects more realistic failure weighting.

Key data

• HARMONi PFS HR (Second-line EGFRm NSCLC)0.52Achieved statistical significance in global trial, but OS missed primary endpoint
• HARMONi OS HR (Second-line EGFRm NSCLC)0.79 (95% CI: 0.62-1.01)Interim analysis, p=0.057, not statistically significant; second interim 0.78 (0.62-0.98), still missed primary endpoint
• HARMONi-A OS HR (China Second-line EGFRm NSCLC)0.74 (95% CI: 0.58-0.95)Final analysis achieved significance, but absolute benefit not significantly different from other failed trials
• HARMONi-2 mPFS HR (China First-line PD-L1 ≥1% NSCLC)0.51Preliminary interim analysis showed PFS benefit
• HARMONi-2 OS HR (China First-line PD-L1 ≥1% NSCLC)0.777Interim analysis not significant; final analysis expected by mid-2026
• HARMONi-6 PFS HR (China First-line All Patients NSCLC)0.60This trial is the focus of ASCO 2026 plenary session, expected interim OS analysis HR >0.722 (not significant)
• PFS-OS HR Average Attenuation (Historical PD-1+VEGF Trials)0.31 (range 0.17-0.47)Aggregated from 8 trials, average attenuation from PFS to OS benefit, ivonescimab's attenuation 0.27-0.28 is moderate
• Second-line EGFRm NSCLC Market Size (US)~$900MBased on 31.5% patients proceeding to second-line, ~7,700 new annual patients, 7-month treatment cycle, $200k pricing
• HARMONi-3 PTS (First-line NSCLC)21%Probability of Technical Success
• HARMONi-7 PTS (First-line PD-L1 High NSCLC)16%Global patients respond better to pembrolizumab, higher success barrier
• HARMONi-GI3 PTS (First-line MSS mCRC)5%MSS patients show poor response to immunotherapy, historical trials show no OS benefit
• SMMT Cash (1Q26)$599MIncludes cash, equivalents, and short-term investments; no revenue source, only expenditures
• Target Price (Bernstein)$7.70Implies 56% downside from reported market price (~$17.50 estimate); based on 12% WACC DCF to 2040
• FDA PDUFA Date (HARMONi Second-line EGFRm NSCLC)2026年11月14日BLA accepted by FDA, but approval prospects rated 'coin toss'
• ASCO 2026 Presentation Date (HARMONi-6)2026年5月31日Plenary session report, base case interim OS analysis HR >0.722 (not significant)

Impact & implications

The report's core implication is a direct blow to investor confidence. As a micro-cap biopharma company with ivonescimab as its sole asset, SMMT faces a 'triple loss' scenario: (1) Second-line NSCLC market is too small and competitive, unlikely to become a pillar product even if approved; (2) First-line NSCLC two-trial success probability only 16%-21%, historical patterns suggest low odds; (3) Colorectal cancer trial is effectively 'for show.' If HARMONi-3, -7, -GI3 all fail (accumulated probability ~95%+), the company, with no other pipeline, faces cash depletion risk post-2027, potentially requiring dilutive financing, acquisition, or bankruptcy. This 'all-in bet on one pipeline' structure poses massive risks to shareholders. Even in the most optimistic scenario of HARMONi second-line approval, considering market size, competition, and penetration, peak revenue is estimated at only ~$200-300M, offering limited support for current valuation. The $7.70 target price reflects this downside scenario's weighted present value.

Risks

• HARMONi6 ASCO 2026 plenary session interim OS analysis failing significance may trigger sharp stock decline
• HARMONi-3 and HARMONi-7 first-line trial failure probability as high as 79%-84%; if both fail, pipeline is left with only second-line commercial prospects
• FDA's heightened OS requirements (Merck HER3-DXd BLA withdrawal as precedent) create HARMONi BLA approval uncertainty
• Second-line EGFRm NSCLC patient pool limited (~7,700 new annual cases), new competitors like Trop-2 ADCs rapidly entering
• SMMT's $599M cash only lasts until mid-2027; trial failures may necessitate financing or acquisition, posing shareholder dilution risk
• HARMONi-GI3 success probability in MSS tumors extremely low (5%), making this indication resource inefficient
• Multiple concurrent trials increase management complexity; single pipeline failure threatens company survival
• China HARMONi-A OS achieved significance (HR 0.74), but global HARMONi failed to replicate, implying regional variation risk
• Ivonescimab's bispecific mechanism lacks preclinical validation, potential underlying scientific issues

What to watch

• May 31, 2026 ASCO plenary session HARMONi-6 results—whether interim OS analysis achieves HR <0.722 threshold
• November 14, 2026 FDA PDUFA decision on HARMONi BLA final approval/rejection
• HARMONi-3 squared patient PFS/OS interim analysis and non-squared patient data readout in H2 2026 to H1 2027
• HARMONi-7 continued enrollment progress and primary completion timeline (currently estimated April 2028)
• China parallel trial HARMONi-GI6 primary completion in January 2027, data presentation as leading indicator for global trial
• SMMT quarterly earnings cash/short-term investment balance changes, assessing cash runway and financing/collaboration dynamics
• Any restructuring or licensing changes between SMMT and AkesoPharmaceuticals regarding ivonescimab regional rights
• Competitor clinical progress in same indications (other PD-L1/VEGF bispecifics, Trop-2 ADCs, KRAS inhibitors, etc.)